阿托伐他汀治疗老年人混合型高脂血症的疗效和安全性  

The Efficacy and Safety of Astorvastatin in Treatment of Combined Dyslipidemia in the Elderly

作　　者：王慧华[1] 卓越[1] 李开沪[1] 朱华[1] 宫玲[1] 

机构地区：[1]上海华东医院心内科,上海200040

出　　处：《中国医药导刊》2002年第4期281-283,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:评估阿托伐他汀治疗老年人混合型高脂血症的疗效和安全性。方法:试验组(阿托伐他汀10mg/d)44例,对照组(辛伐他汀20mg/d)33例,进行随机(4∶3)单盲平行对照试验,观察两组降脂疗效和不良反应发生情况。结果:经过8周治疗,阿托伐他汀组TC、LDLC、TG和(TC-HDL-C)/HDL-C分别下降21％、31％、33％和21％(P<0.01),HDL-C虽有升高5％,但是无统计学上的差别(P>0.05)。组间比较,阿托伐他汀降TC、LDL-C和TG作用明显优于辛伐他汀(P<0.05)。两组不良反应均较轻微和少见。结论:阿托伐他汀10mg/d治疗老年人混合型高脂血症可明显降低TC、LDLC、TC和(TC-HDL-C)/HDL-C,且不良反应轻微,耐受性良好。Objective: To assess the efficacy and safety of astorvastafin in treatment of combined dyslipidemia in the elderiy. Methods: 77 elderly cases with combined dyslipidemia were randomized(4 : 3). single - blind, paralleled divided into two groups, of which astorvastalin 10mg/d for 8 weeks in 44 cases and simvastatin 20mg/d for 8 weeks in 33 cases. The efficacy of the treatment and adverse reactions were observed. Results: After 8 weeks of treatment, TC, LDL-C, TG and (TC - HDL - C)/HDL- C in astor-vastatin group were reduced 21% , 31% , 33% and 21% respectively, P<0.01. Compared with simvastatin, astorvastatin decreased the level of TC, LDL - C and TG, P < 0.05. The adverse reactions of two groups were mild and rare. Conclusion: Astorvastatin 10mg/d is superior to simvastatin in reduction of TC , LDLC , TG and TC - HDL - C)/HDL - C in treatment of combined dyslipidemia in the elderly. The adverse reactions of astorvastatin were mild and can be tolerable.

关 键 词：疗效 安全性 阿托伐他汀 辛伐他汀 老年人 混合型高脂血症 

分 类 号：R589.2[医药卫生—内分泌] R972.6[医药卫生—内科学]